trial

Lurasidone Low-Dose - High-Dose Study Study

NCTId NCT01821378
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 412 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2014-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
412 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-05
Primary completion
2014-06
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Lurasidone Medical Director, MDStudy Director

Sites

66 total
Little Rock, United StatesCerritos, United StatesEscondido, United StatesLong Beach, United StatesLos Angeles, United StatesPasadena, United StatesSan Diego, United StatesSan Diego, United StatesTorrance, United StatesDenver, United StatesMaitland, United StatesMiami, United States

Linked catalysts

1
Lurasidone Low-Dose - High-Dose Study Study — primary completion2014-06

Facts & assertions

4 sourced
Enrollment
412
Phase
PHASE3
Primary Completion Date
2014-06
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lurasidone Medical Director, MD
person